Infringement action filed 24 Sep 2021 in the United States District Court for the District of Delaware and closed 24 Aug 2023, with 4 patents asserted. Recorded basis of termination: case settled.
This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.
The docket lists 4 asserted patents. Full bibliographic detail, drawings and prosecution history for the remaining 2 asserted patents are one query away in Eureka.
Source: case record + Patsnap company data. Attorney names appear as recorded in the docket.Compare both portfolios
Outcome
Basis of termination
From the record · verbatim
"Whereas Plaintiffs Anacor Anacor Pharmaceuticals, Inc. (“Anacor”) and PF PRISM IMB B.V. (collectively, “Plaintiffs”), by their undersigned attorneys, for their Complaint for patent infringement against Defendant Alkem Laboratories Ltd. (“Alkem” or “Defendant”),in this District,Civil Action no .21- 1350 (CFC)(Consolidated into Civil Action No .21-1348(CFC),Charging Defendants with inter alia,infringement of U.S patent Nos.8,039,451, 8,168,614, 8,501,712, and 9,682,092; IT IS HEREBY STIPULATED by Plaintiffs and Defendants,subject to approval of the court: 1.All Claims and Counterclaims between Plaintiffs and Defendants ar Dismissed without Prejudice. 2.Each Party shall bear its own costs,attorneys' fees and expenses incurred in connection with the claims and Counterclaims Dismissed by this order. 3.The parties have entered into a settlement and licence agreement with respect to their respective claims ( Settlement and licence Agreement).Defendants will not make ,have made ,use ,offer for sale or sell the accused product of Defendants in the United States except as provided for in the parties' Settlement and licence Agreement. 4.The Court retains jurisdiction over the parties to this action for purposes of enforcing this Stipulation and order of Dismissal and the Settlement and licence Agreement."
Case 1:21-cv-01348 · D. Del. · closed 24 August 2023
Source: case record, verbatim. The quoted paragraph is the basis-of-termination text as filed.
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
1:21-cv-01348 is a patent infringement action brought by Anacor Pharmaceuticals, Inc. against Alkem Laboratories, Ltd., filed on 24 Sep 2021 in the United States District Court for the District of Delaware. The case closed on 24 August 2023.
Which patents were asserted in 1:21-cv-01348?
US8039451B2 (“Boron-containing small molecules”), assigned to ANACOR PHARMACEUTICALS, LLC, currently active; US8168614B2 (“Boron-containing small molecules as anti-inflammatory agents”), assigned to ANACOR PHARMACEUTICALS, LLC, currently active; US9682092B2 (“Boron-containing small molecules as anti-inflammatory agents”), assigned to ANACOR PHARMACEUTICALS, LLC; US8501712B2 (“Boron-containing small molecules as anti-inflammatory agents”), assigned to ANACOR PHARMACEUTICALS, LLC. The record also lists EUCRISA® Crisaborole ointment,2% and TEVA’S crisaborole ointment, 2%.
How was case 1:21-cv-01348 terminated?
The recorded basis of termination is case settled. The termination text reads: "Whereas Plaintiffs Anacor Anacor Pharmaceuticals, Inc. (“Anacor”) and PF PRISM IMB B.V. (collectively, “Plaintiffs”), by their undersigned attorneys, for their Complaint for patent infringement against Defendant Alkem Laboratories Ltd. (“Alkem” or “Defendant”),in this District,Civil Action no .21- 1350 (CFC)(Consolidated into Civil Action No .21-1348(CFC),Charging Defendants with inter alia,infringement of U.S patent Nos.8,039,451, 8,168,614, 8,501,712, and 9,682,092; IT IS HEREBY STIPULATED by Plaintiffs and Defendants,subject to approval of the court: 1.All Claims and Counterclaims between
What does dismissal without prejudice mean?
A dismissal without prejudice ends this action but leaves the claims alive — the plaintiff may file them again later, subject to the limitation period.
How long did case 1:21-cv-01348 take?
699 calendar days, from filing on 24 Sep 2021 to closure on 24 August 2023.
Who were the attorneys and the judge in 1:21-cv-01348?
Amit H. Thakore, C. Sebastian Zonte, Dimitrios T. Drivas, Elizabeth Chang, Jack B. Blumenfeld, John P. Scheibeler and Megan Elizabeth Dellinger are recorded as counsel for plaintiff Anacor Pharmaceuticals. Kate Harmon, Kevin M. Capuzzi, Louis Constantinou, Manish K. Mehta, Michael S. Weinstein and Samuel J. Ruggio appear for defendant Alkem Laboratories.
Answers reproduce fields from the case record for 1:21-cv-01348 and do not constitute legal advice.Ask your own question
Disclaimer. This page reproduces publicly available court docket data for case 1:21-cv-01348 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.
